62nd ASH Annual Meeting and Exposition: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster I

Oral and Poster Abstracts
Poster

Adult, AML, antibodies, apheresis, apoptosis, autoimmune disorders, Biological, Leukemia, multiple myeloma, Animal models, bone marrow, CLL, Diseases, Non-Biological, biopsy, cell regulation, Combinations, Mantle Cell Lymphoma, Therapies, checkpoint inhibitors, chemotherapy, MDS, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, enzyme inhibitors, white blood cells, T-Cell Lymphoma, Technology and Procedures, Cell Lineage, epigenetics, immunotherapy, Plasma Cell Disorders, Xenograft models, gene editing, Lymphoid Malignancies, Study Population, Clinically relevant, genetic profiling, genomics, Myeloid Malignancies, flow cytometry, TKI, integrative -omics, NGS, molecular interactions, RNA sequencing, pathogenesis, WGS, pathways, signal transduction

940

NSD2 Regulates Pro-Metastatic Gene PTP4A3 through Chromatin Remodeling in Multiple Myeloma

Phyllis SY Chong, PhD¹^*, Jing Yuan Chooi, BSc²^*, Julia Lim, Bsc³^* and Wee-Joo Chng, MBBS, PhD⁴

¹National University of Singapore, Singapore, Singapore
²Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Singapore
³Cancer Science Institute of Singapore, Singapore, Singapore
⁴National University Cancer Institute of Singapore, Singapore, Singapore

941

RPS15 and TP53 Co-Mutation Drives B Cell Malignancy through Altered Translation and MYC Activation in a Murine Model

Catherine Gutierrez^1,2,3, Tamara Ouspenskaia, Ph.D.²^*, Doris Fu^2,4^*, Peyton Waddicor, B.S.^1,5^*, Anat Biran, PhD⁶, Aviv Liani⁷^*, Gregory Lazarian, PharmD^6,8,9,10^*, Elisa Ten Hacken, PhD^1,6,11, Elizabeth Witten³^*, Fara Faye Regis, BS¹²^*, Heather Joyal⁶^*, Leah Billington, BA³^*, Fabienne Lucas, MD PhD^1,13^*, Mei Zheng¹⁴^*, Blake Tye, Ph.D.¹^*, Maria Hernandez-Sanchez, PhD^15,16^*, Miguel Quijada Álamo, MSc¹⁷^*, Shuqiang Li, PhD^2,3,18^*, Binyamin A. Knisbacher, PhD²^*, Ziao Lin, BS^1,2^*, Aziz Al'Khafaji, Ph.D.²^*, Lili Wang, MD, PhD¹⁹, Kenneth J. Livak, PhD^3,18^*, Donna S. Neuberg, ScD^20,21, Florence Cymbalista, MD, PhD^10,22^*, Gad Getz, PhD^1,2,23,24^*, Stirling Churchman, Ph.D.¹^*, Ruben D. Carrasco, MD, PhD^1,25,26^*, Sichen Shao, Ph.D.¹^*, Aviv Regev, Ph.D.¹¹^* and Catherine J. Wu, MD^2,3,27,28

¹Harvard Medical School, Boston, MA
²Broad Institute of MIT and Harvard, Cambridge, MA
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Massachusetts Institute of Technology, Cambridge, MA
⁵Dana-Farber Cancer Institute, Boston, MA
⁶Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
⁷Northeastern University, Boston, MA
⁸INSERM, U978, Université Paris 13, Bobigny, France
⁹Department of Medical Oncology, Dana-Farber Cancer Institute, PARIS, France
¹⁰Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, France
¹¹Broad Institute, Cambridge, MA
¹²Dana Farber Cancer Institute, Boston, MA
¹³Department of Pathology, Brigham and Women's Hospital, Boston, MA
¹⁴Brigham and Women's Hospital, Boston, MA
¹⁵Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain
¹⁶Universidad de Salamanca, IBSAL, Centro de Investigación del Cáncer, IBMCC-CSIC, Salamanca, Spain
¹⁷Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
¹⁸Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA
¹⁹Department of Systems Biology, Beckman Research Institute, City of Hope, Monrovia, CA
²⁰Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
²¹Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
²²INSERM U978, Université Paris 13, Sorbonne Paris Cité, Labex “Inflamex”,, Bobigny, France
²³Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA
²⁴Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, MA
²⁵Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA
²⁶Dept. of Pathology, Brigham and Women's Hospital, Boston, MA
²⁷Department of Internal Medicine, Brigham and Women’s Hospital, Boston, MA
²⁸Department of Medicine, Harvard Medical School, Boston, MA

942

Aberrant Telomere Length and Composition Are Recurrent Features of Myeloid Disorders

Adam Wahida¹^*, Stephan Hutter, PhD²^*, Manja Meggendorfer, PhD², Claudia Haferlach, MD², Wolfgang Kern, MD², Jaroslaw P. Maciejewski, MD, PhD³ and Torsten Haferlach, MD²

¹Torsten Haferlach Leukaemiediagnostik Stiftung, Munich, Germany
²MLL Munich Leukemia Laboratory, Munich, Germany
³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

943

Investigating the Roles of the Yeats Domain in MLL-ENL Mediated Leukemogenesis

Hsiangyu Hu, BS¹^*, Nirmalya Saha, PhD¹^*, Yuting Yang, PhD¹^*, Sierrah Marie Grigsby, PhD¹^*, Rolf Marschalek, PhD²^*, Zaneta Nikolovska-Coleska, PhD¹^* and Andrew G. Muntean, PhD¹

¹Department of Pathology, University of Michigan Medical School, Ann Arbor, MI
²DCAL, Institute of Pharmaceutical Biology, Goethe-University, Frankfurt am Main, Germany

944

Adenylate Kinase 2 Is a Selective Dependency in NSD2-High Multiple Myeloma

Amin Sobh, PhD¹, Charlotte Kaestner¹^*, Jianping Li, MD¹, Alberto Riva, PhD²^*, Richard Lynn Bennett, PhD² and Jonathan D. Licht, MD¹

¹Department of Medicine, University of Florida, Gainesville, FL
²Cancer and Genetics Research Complex, University of Florida, Gainesville, FL

945

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Virginia Olivia Volpe, MD¹, Najla Al Ali, M.Sc²^*, Onyee Chan, MD², Eric Padron, MD³, David A. Sallman, MD² and Rami S. Komrokji, MD²

¹Department of Hematology and Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
³Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

946

Dynamic Epigenetic Landscapes Define Multiple Myeloma Progression and Drug Resistance

Rafael Renatino-Canevarolo, PhD¹^*, Mark B. Meads, PhD²^*, Maria Silva³^*, Praneeth Reddy Sudalagunta, PhD⁴^*, Christopher Cubitt⁵^*, Gabriel De Avila, BS⁶^*, Raghunandan R Alugubelli, MS⁷^*, Amit Kulkarni, PhD⁸^*, Qi Zhang, PhD⁹^*, Oliver Hampton⁸^*, Kenneth H. Shain, MD, PhD ¹⁰ and Ariosto Siqueira Silva, PhD¹¹^*

¹H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
³Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
⁴Cancer Imaging and Metabolism, H Lee Moffitt Cancer Center, Tampa, FL
⁵Moffitt Cancer Center, Tampa, FL
⁶Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
⁷Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
⁸M2GEN, Tampa, FL
⁹M2Gen, Tampa, FL
¹⁰Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Saint Petersburg, FL
¹¹Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

947

Interrogation of Dysregulated Pathways Enables Precision Medicine in Mantle Cell Lymphoma

Yang Liu, PhD¹^*, Shuangtao Zhao, PhD²^*, Changying Changying Jiang, PhD¹, Yixin Yao, PhD³, Joseph McIntosh, BS¹^*, Alexa A Jordan, BS¹^*, Yijing Li, MS¹^*, Yuxuan Che¹^*, Preetesh Jain, MBBS, MD, DM, PhD¹, Linghua Wang, PhD²^* and Michael Wang, MD^1,4

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
⁴Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

948

The Involvement of STAT/SOCS Signaling in miRNA-Induced T Cell Exhaustion in Cutaneous T-Cell Lymphoma

Zhen Han^1,2^*, Chingyu Su^2,3^*, Renee J. Estephan, BS^1,2,4, Xiwei Wu, PhD⁵^*, Sung Hee Kil, PhD^1,3,4^*, Steven T. Rosen, MD^6,7,8 and Christiane Querfeld, MD, PhD^3,7,9,10

¹Division of Dermatology, City of Hope, Duarte, CA
²Beckman Research Institute, City of Hope, Duarte, CA
³Division of Dermatology, Beckman Research Institute, City of Hope, Duarte, CA
⁴Irell and Manella Graduate School of Biological Sciences, City of Hope, Duarte, CA
⁵Department of Molecular and Cellular Biology, City of Hope National Medical Center, Duarte, CA
⁶Department of Hematology/HCT, City of Hope Medical Center, Duarte, CA
⁷Beckman Research Institute, Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA
⁸Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, CA
⁹Beckman Research Institute, City of Hope Medical Center, Duarte, CA
¹⁰Department of Pathology, City of Hope, Duarte, CA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

602.P1.27 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster I